

Participant name: Hospital ID: CHI/Date of Birth:

| - | |
|--------|--|
| | |
| | |
| Birth: | |
| mun. | |
| | |

| SOPHIST - SO Sponsor Chief Investigat IRAS number | agliflozin in Patients with Heart failure Symptoms and Type 1 Diabetes University of Dundee-NHS Tayside or Dr Ify Mordi 1007807 | | | |
|---|--|--|--|--|
| Principal Investi | gator | | | |
| Contact number | | | | |
| Contact email | | | | |
| Visit 8 | | | | |
| Date of visit: | Participant trial ID | | | |
| Please tick to indicate the following have been completed: | | | | |
| Confirmed participant's identity | | | | |
| Participant has verbally given their consent to continue in the trial | | | | |
| Concomitant medications have been reviewed | | | | |
| Adverse events have been reviewed | | | | |
| Educati | Education/review of glucose and ketone management undertaken including | | | |
| hypogly | caemic and DKA events, glucose/ketone readings, and insulin doses | | | |

| NT TA GIASS | NYHA | Class | |
|-------------|------|-------|--|
|-------------|------|-------|--|

The following must be filed in the participant's medical notes:

- Changes to concomitant medications since last visit
- Any adverse events since last visit
- Details of review of diabetes management including any changes to insulin or other diabetes medication
- Any hypoglycaemic and DKA events since last visit
- Any other notable findings and actions taken
- If the participant was withdrawn from the trial at this visit, document reason

Any further information of note:



| Participant name: |
|--------------------|
| Hospital ID: |
| CHI/Date of Birth: |

Visit has been carried out as per protocol